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Abstract
Background: Advances in genomics offer promise for earlier detection or prevention of cancer, by personalisation
of medical care tailored to an individual’s genomic risk status. However genome sequencing can generate an
unprecedented volume of results for the patient to process with potential implications for their families and
reproductive choices. This paper describes a protocol for a study (PiGeOn) that aims to explore how patients and
their blood relatives experience germline genomic sequencing, to help guide the appropriate future
implementation of genome sequencing into routine clinical practice.
Methods: We have designed a mixed-methods, prospective, cohort sub-study of a germline genomic sequencing
study that targets adults with cancer suggestive of a genetic aetiology. One thousand probands and 2000 of their
blood relatives will undergo germline genomic sequencing as part of the parent study in Sydney, Australia
between 2016 and 2020. Test results are expected within12–15 months of recruitment. For the PiGeOn sub-study,
participants will be invited to complete surveys at baseline, three months and twelve months after baseline using
self-administered questionnaires, to assess the experience of long waits for results (despite being informed that
results may not be returned) and expectations of receiving them. Subsets of both probands and blood relatives will
be purposively sampled and invited to participate in three semi-structured qualitative interviews (at baseline and
each follow-up) to triangulate the data. Ethical themes identified in the data will be used to inform critical revisions
of normative ethical concepts or frameworks.
Discussion: This will be one of the first studies internationally to follow the psychosocial impact on probands and
their blood relatives who undergo germline genome sequencing, over time. Study results will inform ongoing
ethical debates on issues such as informed consent for genomic sequencing, and informing participants and their
relatives of specific results. The study will also provide important outcome data concerning the psychological
impact of prolonged waiting for germline genomic sequencing. These data are needed to ensure that when
germline genomic sequencing is introduced into standard clinical settings, ethical concepts are embedded, and
patients and their relatives are adequately prepared and supported during and after the testing process.
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Background
Despite substantial therapeutic progress, over one-third
of patients diagnosed with cancer will die of their disease
[1]. Early risk identification and/or detection of cancer is
vital to improving outcomes through prevention and
early diagnosis, with the potential to increase the cancer
cure rate.
Cancer may be regarded as the product of cumulative
somatic genetic mutations, with some arising in individ-
uals with a germline variant conferring an increased risk,
modified by environmental exposures. It is estimated
that the heritable component of common cancers such
as colorectal, breast and prostate cancer contribute to
25–50% of their aetiology, [2] although the majority of
this percentage remains to be elucidated [3, 4]. Advances
in genomics offer great promise toward improving out-
comes in prevention. The introduction of massively par-
allel sequencing has rapidly reduced the cost and
processing time of germline genomic sequencing (GGS),
and as a result, an unprecedented amount of both som-
atic and germline information has been generated [5].
Advances including the ability to test multiple genes in a
single panel instead of individual genes, and GGS, have
been particularly important in achieving increased access
to genomics [6]. These developments have the potential
to immediately impact clinical care through production
of an exponential increase in information about germline
cancer genetics, which in turn may assist in the gener-
ation of knowledge to identify those at increased risk [7].
The cost and effectiveness of screening and prevention
programs in general is dependent on targeting high-risk
populations [8]. Clinical criteria for hereditary cancer
based on family history – the most common criteria to
inform current practice - do not identify all variant car-
riers and are unlikely to identify de novo mutations, re-
cessive alleles, or multiplicative effects of polygenic risk
[9]. The capacity to define who is at increased risk, and
perhaps just as importantly, who is not at increased risk,
has both individual and public health implications.
Genomic sequencing to define an individual’s risk may
soon offer a universal, acceptable and cost-effective
method of personalising medical prevention strategies
tailored to genetic status that predicts risk of developing
new cancers. This study will focus on GGS. A second
study examining the psychosocial and ethical issues and
outcomes of tumour genomic profiling for patients with
advanced cancer is underway and is described in a separ-
ate paper. These two studies comprise the P (psycho-
social) I (in) GE (genomic) ON (oncology) Project.
GGS determines the complete DNA sequence of an
organism’s genome which in humans, includes ~ 20,000
genes [10]. GGS can reveal germline genetic variants
that may also affect blood relatives, that are: i) relevant
to the target cancer and clinically actionable, guiding
risk prevention; ii) relevant to the target cancer but not
clinically actionable, (no proven treatments); iii) inciden-
tal (relevant to other cancers and diseases) and clinically
actionable, guiding risk prevention; iv) incidental and
not clinically actionable (no proven treatments); or v) of
unknown or uncertain significance. Depending on a
test’s methods and filtering, results of GGS can be highly
complex [11].
Individuals with pathogenic germline variants that sig-
nal high risk of a particular disease(s) (and their blood
relatives) can be offered more intensive risk manage-
ment. But GGS will only realize its potential in an effect-
ive and ethically appropriate way if patients can
understand, manage, and make informed decisions to
pursue health recommendations based on genomic re-
sults. A number of challenges inherent in GGS present
barriers to these outcomes.
Although uncertainty pervades medical information,
its scope in genomics may be unprecedented [12]. Han
et al.’s taxonomy of medical uncertainties in clinical gen-
ome sequencing [13] identifies three principal sources of
uncertainty: indeterminate outcomes (probability), im-
precise risk estimates, and complexity. Given that the
science of linking genetic variants to disease risk is in its
nascent stage, practitioners who obtain patient consent
for GGS face a challenge in communicating these uncer-
tainties to guarantee informed choice and reduce unreal-
istic expectations. At the same time, patients must
absorb and cope with a large amount of information
both before sequencing (during the consent process),
after sequencing (during the return of results), and at
follow up [14].
Patient uncertainty and poor tolerance of ambiguity
has been found to reduce patient willingness to receive
GGS results [15–17]. While patient autonomy and
shared decision-making are recognized values in Austra-
lian health care, what information patients want or
should be told, and how uncertainty should be
approached in GGS, is not well understood [18]. In view
of the fact that uncertainty will continue to pervade
GGS for years to come, it has been suggested that, ra-
ther than seeing uncertainty as something that needs to
be eradicated, it should be embraced as a part of the
process, with communication in the therapeutic relation-
ship adapted to support the patient appropriately [19].
Debate is ongoing; and represents “arguably the most
pressing issue in genetics today” [20].
The psychological impact of single gene testing has
been well studied, particularly in the context of heredi-
tary breast and ovarian cancer, Lynch syndrome and
melanoma [21]. The evidence suggests that distress
lessens or remains stable for those found not to have a
pathogenic variant, and while there is often an initial in-
crease in distress for those found to have a gene variant,
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distress generally returns to normal levels in the longer
term [22, 23]. We note that there are important differ-
ences between genome sequencing and single gene test-
ing that have implications for psychological outcomes,
making it unlikely that single gene results will generalize
to whole genome sequencing. First, in GGS, there can
be (depending on reporting/filtering methods) an unpre-
cedented volume of results to process. The potential for
incidental findings means that both patients and families
may be faced with risks they had not been seeking nor
were prepared to learn. Second, the high incidence of
findings of unknown/uncertain significance, whose
meaning may or may not become clearer over time, may
be confusing and worrying to patients and families.
Third, results may be both diagnostic and predictive,
each with traditionally different ethical norms guiding
clinical practice [24, 25]. Thus psychosocial and ethical
assessment of GGS is critical to guide implementation
into mainstream medicine.
There has also been a question raised regarding
whether GGS can deliver behavioural change in cancer
care, as several studies of allegedly healthy participants
have indicated that this was not always the case follow-
ing receipt of actionable results [26–30]. Most partici-
pants in these studies seemed not unduly concerned or
distressed about their health at short-term follow-up,
and did not change their lifestyle or start more intensive
screening. However, it is not clear whether these results
could be extrapolated to a cancer context, where pa-
tients are more likely to view the disease as very serious
and to seek optimal treatment and/or prevention [31].
The vast majority of genetic studies in hereditary cancer
families have reported that the majority of participants
change their behaviour including undergoing prophylac-
tic surgery [32–34].
Research to date has revealed cautious interest in gen-
omic testing in the general population. Several Austra-
lian studies have found limited knowledge about, and
little interest in pursuing, direct-to-consumer personal
genomic testing amongst the general public, [35] who
have also expressed significant concerns about issues
such as privacy and potential discrimination [35–38].
Interest among cancer patients appears stronger [39].
A US study [40] exploring hypothetical responses to an
offer of GGS, found that many cancer patients were in-
terested in testing, and had more faith in genomic over
standard test results. Patients appear to value these tests
sufficiently to pay substantial amounts of money
($1000–$2000 for a pharmacogenomic test evaluating
likely response to particular drugs) and to wait for their
results for up to two weeks [41]. Most patients in this
latter study wanted to be involved in decision-making
about the test, but one in five lacked a basic understand-
ing of this approach, a result also found in other studies
[16, 35]. There is evidence that previous experience of
illness and/or family history of disease can impact atti-
tudes [42–45]. However, it is salient to remember that
although hypothetical scenarios for Huntington’s Disease
implied that 85% at risk would take up mutation testing,
in practice only 15% did [46].
Overall, there is insufficient understanding of the pref-
erences, attitudes and values of cancer patients who have
actually had GGS: their expectations, their experience of
uncertainty, or the psychological effects of testing. The
Clinical Sequencing Exploratory Research studies [47]
and ClinSeq [48] are currently collecting data in appar-
ently healthy individuals, but no studies of cancer pa-
tients who have actually undergone GGS testing have
reported longitudinal data. Furthermore, no studies have
explored the impact of GGS on blood relatives, yet
germline findings have potential implications for blood
relatives as for patients. It is important to explore how
patients and, blood relatives value and experience GGS,
and cope with prolonged uncertainty, non-actionable re-
sults and incidental findings, as well as informative find-
ings, before GGS enters routine clinical practice.
This report will outline the first Australian study to
collect longitudinal data on cancer patients’ experiences
of GGS, and one of the first studies internationally to
follow probands and their blood relatives who undergo
GGS, over time. The study results will inform ongoing
ethical debate and clinical practice development on is-
sues such as protocols for obtaining informed consent
for GGS, and informing people and their relatives re-
garding genomic results. The study will also provide crit-
ical outcome data concerning the psychosocial impact of
waiting for GGS results on patients and their blood rela-
tives. These data are needed to ensure that when GGS is
introduced into routine clinical care, ethical concepts
are embedded, and patients and their relatives are ad-
equately prepared and supported during and after the
testing process.
Guiding theory
There is a strong evidence base supporting the use of so-
cial cognition models to provide a structured framework
for identifying psychosocial and cognitive influences on
health behavior including, genetic testing [49]. This
study’s design is guided by Protection Motivation Theory
[50] and Differentiation and Consolidation theory [51].
Protection Motivation Theory proposes that we defend
ourselves according to the apparent severity and prob-
ability (vulnerability) of danger, apparent effectiveness of
protective behaviour, and apparent self-efficacy in exe-
cuting the protective behaviour. Differentiation and
Consolidation theory asserts that decision-making in-
volves a method of ongoing differentiation including:
recognizing options with apparent critical attributes,
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prioritising one or two possibilities based on highly rated
attributes and reassessing an initial preference on the
basis of new information. This is followed by a consoli-
dating process, which emphasises one’s values, and fu-
ture potential outcomes, to favourably support the
chosen route and thereby prepare for possible threats,
regret and doubt.
In this study, protection motivation will ensue from
perceived susceptibility to disease risk, and/or fear of
cancer progression, as well as participant and proband
knowledge of, attitudes to, and value given to, GGS (as a
strategy to guide more effective screening and thus re-
duce the threat of cancer development). Patients who
understand GGS to be valuable will be prone to remain
satisfied with their decision to undertake GGS, over
time. Intolerance of uncertainty may make GGS less at-




The aim of this study in people who undergo GGS is to:
1) evaluate the impact of testing on cancer-related
anxiety, patients’ and blood relatives’ perceived
value of genomic information, and
2) undertake a critical reflection on all results, with
reference to relevant ethical issues and concepts.
Primary outcomes
1. The primary psychosocial endpoint is: impact of
testing on cancer-related distress, measured by
change in the Multidimensional Impact of Cancer
Risk Assessment (adapted) Scale.
2. The primary attitudinal endpoint is: patients’ and
blood relatives’ perceived value of genomic
information measured by a hypothetical time trade-
off scenario.
3. The primary ethical outcome is: a critical reflection
on all results, within reference to a range of
normative ethical issues and concepts.
Secondary outcomes
1. Secondary psychosocial /ethical outcomes include
significant changes in scores of any of the
following: Impacts of Events Scale Hospital Anxiety
and Depression Scale; Fear of Cancer Occurrence/
Recurrence/Progression; Herth Hope Scale; risk
perception; perceived susceptibility to cancer; and
perceived likelihood of having a pathogenic variant.
2. Secondary attitudinal outcomes include:
understanding of GGS; views on disclosure of
genomic information; perceived benefits and
drawbacks of GGS.
3. Secondary decisional outcomes include: degree of
decisional satisfaction and regret.
Parent study
The Genomic Cancer Medicine Program, funded by the
NSW Ministry of Health, Australia, involves the parent
study, Genetic Cancer Risk in the Young (Cancer Risk)
Study. This study is prospectively recruiting 1000 cancer
patients with features suggestive of a genetic aetiology.
Two thousand first degree blood relatives of the cancer
probands will also be recruited. Both probands and rela-
tives will be offered GGS. The Cancer Risk Study partici-
pants will receive results 12–15 months after initial
enrolment if actionable results are found, and study par-
ticipants wish to receive them. Risk management will be
offered within a clinical trial setting as part of a separate
funded study, the Surveillance in Multi-Organ Cancer
prone syndromes study. Patients and blood relatives will
be recruited to the Cancer Risk psychosocial study when
they give written consent to the Cancer Risk Study. Thus
they will have already considered and given consent to
GGS but not yet had GGS testing.
The current PiGeOn study represents a sub-study of a
germline genomic study targeting people with cancers
likely to have genetic aetiology.
This study is led by the Psycho-Oncology Co-operative
Research Group based at the University of Sydney,
Australia. The project was funded by a project grant
from the National Health and Medical Research Council,
Australia, and ethics approval was given by the Human
Research Ethics Committee at St Vincent’s Hospital,
Sydney.
Research design
This study is a mixed method, prospective, cohort sub-
study of a GGS program recruiting probands with a his-
tory suggestive of a genetic aetiology and two of their
first-degree blood relatives.
Setting
Participants will be recruited by the parent study, from
incident and prevalent cases at oncology units in Sydney
hospitals. All eligible participants will be asked to give
consent using established protocols for genetic research,
validated by large genetic studies, the Kathleen Cuning-
ham Foundation Consortium for research into Familial
Breast cancer [52] and the International Sarcoma Kin-
dred Study [53]. This consent covers GGS as well as psy-
chosocial questionnaires and interviews. Participants can
elect whether and which type of results (i.e. ‘gene variant
that causes cancer’, ‘incidental finding that may be
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important to my health’) they want returned. Reporting
of variants of uncertain significance will not be offered.
Participants
Inclusion criteria include having a histologically con-
firmed malignancy, age 16–40 years at diagnosis, or an
individual with > 1 primary cancer diagnosed < 50 yrs. of
age or an individual with > 2 primary cancers at any age;
first degree relative aged 18 years or over of an individ-
ual meeting the above criteria or a cancer affected blood
relative aged 18 years or older of an individual meeting
the above criteria; willing and able to comply with all
study requirements, including timing and/or nature of
required assessments; signed, written informed consent
to participation in GGS.
Exclusion criteria include: inability to understand an
English language consent form.
Procedure for PiGeOn
As seen in Fig. 1, participants will be asked to complete
a questionnaire at baseline, 3 months after baseline (fol-
low-up 1) and 12 months after baseline (follow-up 2). It
is expected that no participant will have received results
before follow-up 2. These timeframes were chosen to
allow impact of prolonged uncertainty to be explored. A
subset of both proband and blood relative groups (ap-
proximately 25 participants each) will be asked to par-
ticipate in semi-structured interviews in parallel with
questionnaire time points to further investigate attitudes
towards GGS and its psychosocial, and ethical aspects.
Measures
Patient-reported outcomes will be measured according
to the following schedule (see Table 1).
The following outcome measures will be administered
at baseline only:
Demographic data
Age, gender, marital status, ancestry, language spoken at
home, medical history, family history of cancer, lifestyle
habits, socio-economic variables and history of genetic
screening will be gathered by patient report.
The following validated (some adapted) outcome mea-
sures will be administered at baseline only:
Perceived importance of GGS
This 5-item measure adapted from Hay et al. [54] assesses
perceived importance of genetic information to the partici-
pant, using a Likert scale. Specifically, the questions pertain
to importance of learning about how genes affect the
chance of developing cancer or other diseases, how lifestyle
affects the chance of getting cancer or other diseases, and
how much control the participant feels over whether they
would develop cancer in the future. High scores indicate
greater importance.
Knowledge
An 8-item, multiple choice, study-developed question-
naire assessing knowledge of the purpose of GGS, likely
frequency of informative results, cancers in which in-
formative results are more likely to be found, availability
Fig. 1 Study Procedure. Cancer risk PS study: Cancer risk
psycho-social sub-study
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of tailored risk-management or treatment options, and
source of genetic knowledge. Scores are summed, with
high scores indicating greater knowledge.
Preferences for who should be tested
Three items to assess participants’ views on who should
receive GGS if it were clinically available, for comparison
with a previous study [55].
Value of GGS
A hypothetical time trade-off scenario based on those used
in three previous studies [41, 56, 57]. Six items assess how
the likelihood of finding an informative result impacts will-
ingness to have GGS, and the amount the participant
would be willing pay for GGS (from $0 to $10,000) if GGS
found an informative result in 1, 10, 20, 30, 40 or 50 people
out of 100.
Preferences for being informed of results
Four Likert-scale items adapted from Tabor et al., [58]
assessing desire for results informing: treatment,
prognosis, and risk of other cancers (yes / no / maybe /
don’t know).
Self-efficacy
Four items adapted from Rosenburg et al., [59] assessing
perceived ability to cope if actionable, non-actionable,
incidental or germline results are found. High scores in-
dicate greater perceived ability to cope.
Anticipated behavioural change
Seven Likert-scale items developed from the literature to
measure the participant’s anticipated likelihood of be-
havioural change in the event of receiving a positive re-
sult for cancer risk. Higher scores indicate stronger
intention to change behaviour. This item is included for
comparison with a future study. Study-developed.
Tolerance for uncertainty
This measure from Kasparian et al. [60] includes 8
Likert-scale items to assess reaction to uncertainty, am-
biguity and the future. High scores indicate greater
intolerance.














Perceived importance of GGS Adapted from Hay et al. [54] x
Knowledge Study-developed x
Preferences for who tested Ballinger et al. [55] x
Value of GGS Adapted from previous studies [41, 56, 57] x
Result return preferences Ballinger et al. [55] x
Perceived benefits and drawbacks of GGS Adapted from Jamal et al. [61] x x
Anticipated behavioural change Study-developed x
Psychological factors
Coping with uncertainty Kasparian et al. [60] x
Self-efficacy Adapted from Rosenberg et al. [59] x
Perceived susceptibility Kasparian et al. [60] x x x
Psychological outcomes
Coping with waiting for GGS results Multidimensional impact of cancer risk assessment
(adapted) [64]
x x
Fear of cancer (recurrence) Concerns about Recurrence Questionnaire [67] x x x
Cancer specific anxiety Impact of events scale [62] x x
Anxiety and depression Hospital anxiety and depression scale [63] x x
Hope Herth Hope Index [65] x x
Decisional outcomes
Decisional satisfaction Satisfaction with Decision Scale [68] x x x
Decisional regret Decision Regret Scale [66] x x
GGS germline genome sequencing
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The following outcome measures will be administered
at the first and second follow-ups:
Perceived benefits and drawbacks of genetic panel testing
Nine Likert-scale items and two open-ended questions
adapted from an earlier study [61] assessing perceived
specific benefits and drawbacks of GGS.
Cancer specific anxiety
The 15-item Impact of Events Scale (IES) [62] assesses
cancer related anxiety, in two subscales, intrusive think-
ing and avoidance. High scores indicate greater cancer-
related anxiety.
Anxiety and depression
The 14-item Hospital Anxiety and Depression Scale
(HADS) [63] comprises two 7-item sub-scales measuring
anxiety and depression. High scores indicate greater
morbidity.
Coping with waiting for results
Twenty-three items from the Multidimensional Impact
of Cancer Risk Assessment [64] assessing impact of wait-
ing for results of genetic testing. High scores indicate
greater distress.
Hope
The 12-item Herth Hope Index (HHI) [65] measures
hope and sense of meaning, with three subscales: tem-
porality and future, positive readiness and expectancy,
and inter-connectedness. High scores indicate greater
hope.
Decisional regret
The 5-item Decisional Regret Scale (DRS) [66] measures
health care decision regret about the decision to have
GGS. High scores indicate greater regret.
The following outcome measures will be administered
at baseline and all follow-ups:
Perceived susceptibility
Three items where participants indicate perceived likeli-
hood of having a gene fault that increases risk of cancer
occurrence or progression from ‘much lower’ (0) to
much higher [4], and also on a visual analogue scale (0–
100%) [60].
Fear of cancer occurrence/progression
The five-item Concerns about Recurrence Questionnaire
(CARQ), [67] adapted to measure fear of cancer devel-
opment or progression. High scores indicate greater fear.
Satisfaction with decision to have GGS
The 6-item Satisfaction with Decision (SWD) scale [68]
measures satisfaction with decision to have GGS. Items
are rated on a Likert scale. High scores indicate greater
satisfaction.
Qualitative interviews
A subset of probands (n = 20–40) and their participating
blood relatives (n = 20–40) will be invited to participate
in three semi-structured interviews (at baseline and each
follow-up). Probands and relatives will be interviewed
separately to encourage greater openness. Interviews will
explore views on who should be offered GGS, attitudes
to disclosure of results, perceived benefits and challenges
of GGS and experiences of waiting for results. Both co-
horts will be sampled purposively to include a wide var-
iety of experiences, including individuals with and
without a cancer diagnosis. Recruitment will continue
until data saturation is reached.
Qualitative data analysis
Interviews will be recorded and transcribed verbatim.
Transcripts will be coded and themes will be developed
through the Framework Analysis method [69]. This the-
matic analysis allows comprehensive and transparent
data analysis within a large cohort, and for data compar-
isons both across and within participants, making it well
suited to longitudinal data collection. Qualitative results
will inform the quantitative results.
Ethical analysis
Ethical concepts and analysis will be pertinent for the
whole of this study, and will be iteratively and critically
reflected upon as the project proceeds. Survey items
allowing free-text responses regarding benefits and
drawbacks of GGS will allow the investigating team to
examine whether any responses support the identifica-
tion of relevant ethical themes; such as how participants
view autonomous decision-making or cost consider-
ations. Findings from qualitative interviews will be critic-
ally compared with bioethics literature regarding
concepts such as family communication, duties to dis-
close, what constitutes autonomous decision-making (in-
formed consent), approaching uncertainty in GGS and
determining when it is appropriate to offer testing; and
to whom. The result will be a series of normative posi-
tions, supported by empirical data [70, 71].
Quantitative data analysis
Mean differences in outcomes will be compared using t-
test (continuous) or chi-squared tests (dichotomous).
Non-parametric tests will also be used where appropri-
ate. Temporal changes in scales will be investigated by
calculating the difference between time-points. Multiple
Best et al. BMC Cancer  (2018) 18:454 Page 7 of 10
(continuous outcomes) or logistic (dichotomous out-
comes) regression will be employed to adjust for the ef-
fect of confounders and identify predictors of outcome.
The correlation structure between blood relatives or
when outcomes are analysed over more than 2 time
points will be suitably adjusted for when needed using
mixed effects models. Linear mixed models and logistic
mixed models will be performed in R: A language and
environment for statistical computing employing pack-
age nlme for the linear mixed model and lme4 for the
logistic mixed model. Assumptions of normality of resid-
uals and homogeneity of variance will be confirmed
visually though diagnostic residual plots. Multivariable
models will be created with the inclusion of all potential
confounders, and those predictors that show little evi-
dence for an association with the outcome in univariate
analysis. Backwards elimination followed by forwards
addition will be employed to select predicting variables
in the final model. Known and identified confounders
will be incorporated regardless of their statistical signifi-
cance. Collinear independent variables will be identified
and eliminated.
Sample size
The parent study plans to recruit 3000 probands in total
over three years. With a conservative retention and sur-
vival estimate of 75%, this is reduced to at fewest 469 pa-
tients per cohort. With this sample size estimate, using a
significance level of 0.05 this project: has 90% power to
estimate the perceived value of genomic information in
each time trade-off category of all patients and blood
relatives to a margin of error of at most 5%; and estimate
other secondary outcomes with adequate precision. Mul-
tiple regression on each cohort with at most 24 explana-
tory variables (including dummy variables) has 90%
power to detect significant categorical variables with 5
categories (largest possible categorical variable) when
that predictor explains greater than 3.6% of the residual
variance, or to detect a continuous variable when it ex-
plains more than 2.3% of the residual variance.
Discussion
The PiGeOn study will contribute to the literature by
identifying the knowledge, values, attitudes and coping
strategies of patients and their blood relatives with
regards to GGS. The project aims to determine how
these, and other factors, predict subsequent cancer-
related behaviour and psychosocial outcomes (in associ-
ation with a future study). This study will also describe
these factors’ alignment with current ethical norms. This
will be the first Australian study to collect longitudinal
data on cancer patients’ experience of GGS, and one of
the first studies internationally to follow probands and
their blood relatives who undergo GGS, over time.
The parent study, the Cancer Risk in the Young Study,
will involve participants who have the experience of a
prolonged wait time until GGS results are available, and
the majority of participants will receive no results (as
will be explained during the consent process). Despite
being advised that it is unlikely that a pathogenic gene
variant will be identified, previous studies involving
healthy participants suggest that patients have high ex-
pectations for the usefulness of returned results, and
may therefore continue to hope for, and possibly worry
about, results nonetheless [48]. The timing of the assess-
ments allow the psychosocial impact of this wait time to
be explored based on Protection Motivation Theory. Re-
sults from this study will be linked with subsequent
studies to explore patient responses to results including
lifestyle change and pursuing genetic counselling.
A qualitative component has been included in order to
capture and explore the complexity of patient expecta-
tions, the experience of uncertainty, their understanding
of the implications of testing and their attitudes towards
sharing results, which may have familial repercussions.
Motivation for testing, information needs and prefer-
ences are expected to vary and qualitative research has
value in understanding processes.
Genomic screening, both tumour and germline, is
likely to become widespread in healthcare, and to influ-
ence cancer prevention, diagnosis, treatment and risk-
management. GGS generates information of unprece-
dented volume, some of which will have uncertain sig-
nificance, the meaning of which will change over time. It
gives rise to testing methods that are both diagnostic
and predictive and lead to implications for communica-
tion within families and reproductive choice on a scale
which we have previously never had to manage in
healthcare. The study results will inform ongoing ethical
debate on issues relevant to the large-scale introduction
of GGS into the clinical setting, such as protocols for
obtaining informed consent for GGS as well as assenting
to unknown future research, and informing (or not
informing) patients and their relatives regarding gen-
omic results. The study will also assess whether there
are psychosocial sequelae following GGS testing, after
being informed that results for patients and their blood
relatives may not be forthcoming. Results will be linked
to further studies to inform understanding of behaviour
following receipt of results. These data are needed to en-
sure that when GGS is commenced as part of routine
clinical care, ethical principles are well-established in
practice, and patients and their relatives receive suffi-
cient preparation and support before, during and after
GGS testing. While this cohort is a selective sample with
risk factors suggestive of a germline mutation such as
young age of onset or multiple primaries, understanding
the influences on behavioral change will also increase
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the likelihood that the introduction of germline genomic
cancer screening for the general population will have the
hoped-for positive benefits.
Given the scarcity of evidence on responses to actual
GGS for cancer, this study is an important and timely
step in filling the critical gaps in understanding about
the best way to introduce GGS into clinical medicine.
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